MedTrace Logo

Olinvacimab With Pembrolizumab in Patients With mTNBC

NCT04986852 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-12-30

No results posted yet for this study

Summary

The objective is to evaluate the efficacy and safety of Olinvacimab in combination with Pembrolizumab in patients with mTNBC.

Conditions

  • Metastatic Triple-Negative Breast Cancer

Interventions

DRUG

Olinvacimab

Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).

Sponsors & Collaborators

Principal Investigators

  • Claire Beecroft, Ph.D, MD · Hollywood Private Hospital, Australia

  • Dhanusha Sabanathan, Ph.D, MD · Macquarie University, Australia

  • Brenton Seidl, Ph.D, MD · University of Sunshine Coast, Australia

  • Daphne Day, Ph.D, MD · Monash Medical Centre, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2024-12-03
Completion
2024-12-03

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04986852 on ClinicalTrials.gov